Laying the Groundwork for a Biotech Rebound
Despite the spring’s bad headlines, this summer ended with a pile of venture capital deals and two more Bay State biotech IPOs. It’s time for Beacon Hill to do its part to keep that momentum going.
Despite the spring’s bad headlines, this summer ended with a pile of venture capital deals and two more Bay State biotech IPOs. It’s time for Beacon Hill to do its part to keep that momentum going.
Massachusetts’ life science industry added R&D jobs but lost traction in biomanufacturing, a hoped-for source of new jobs and economic growth outside of the Greater Boston cluster.
As the MBTA Communities law expands its reach to an additional 130 Massachusetts cities and towns in 2024, Gov. Maura Healey appealed to business leaders to step into the fray and lobby their hometowns to expand multifamily zoning.
A major source of funding for Massachusetts life science companies dropped sharply in 2022, but still exceeds pre-pandemic investment levels.